Joseph Walker is a Reporter at The Wall Street Journal. He covers a range of topics within the pharmaceutical and biotech sectors, focusing on medicine and healthcare, including alternative medicine and health and wellness. Joseph's work has been featured in notable publications such as The Globe and Mail, Reuters, Yahoo Finance, and LiveMint.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Joseph Walker's coverage is heavily focused on the health and healthcare industries, particularly regarding pharmaceutical companies, drug approvals, regulatory actions by government agencies like the FDA, and policy developments affecting drug prices. He has a specific focus on US-based news.
If you are reaching out to Joseph with a pitch or as a potential source, ensure that your expertise aligns with these areas of interest. Topics such as FDA approval processes for new drugs, investigations into health insurers' role in driving up drug costs, and industry responses to regulatory changes could be particularly relevant based on his recent articles.
Given his high percentage of press releases cited in coverage attributes (23%), providing access to exclusive data or insider perspectives related to major announcements from pharmaceutical companies or healthcare institutions may increase the likelihood of getting noticed by Joseph.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Joseph Walker
Walgreens Boots Alliance posted a $3 billion quarterly loss, driven largely by tax charges and a write-down on its investment in a Chinese pharmacy chain. Walgreens also gave more detail on the downsizing it first revealed in June, saying it had settled on closing 1,200 stores in the next three years, including about 500 in the next year. Shuttering stores is expected to boost adjusted earnings per share and free cash flow immediately, Walgreens said.
By: Joseph Walker
Walgreens Boots Alliance posted a large quarterly loss while stepping up efforts to execute on Chief Executive Tim Wentworth’s turnaround strategy. The embattled U.S. pharmacy and healthcare chain is closing unprofitable stores, negotiating better reimbursement terms with insurers, and dialing back investments in primary care clinics. Walgreens will close 1,200 stores over the next three years, Wentworth said Tuesday, including about 500 in the next year.
Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. The early-stage data furnishes proof that Wave’s approach to editing RNA could work in other diseases, and came as a pleasant surprise given that some analysts had expected that multiple doses of the treatment, codenamed WVE-006, would be needed to have a pronounced effect.
Greater use of obesity drugs and other pricey medicines helped spur Cardinal Health to a fiscal first-quarter earnings beat, boosting its share price as well as competing drug distributors. Sales in Cardinal’s pharmaceutical unit jumped 16% to $530 million, and a little less than a third of the increase came from anti-obesity drugs, such as Novo Nordisk's Wegovy and Eli Lilly’s Zepbound.
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the drugmaker says.
A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a midstage study. Subjects taking Amgen’s MariTide lost 20% of their body weight compared with those who received placebos, Amgen said Tuesday. Analysts had generally expected the drug to achieve weight reduction of 20% or more.
John McCullough, Carencro, LA — John McCullough, known affectionately as "UnderDog," passed away on December 6th, 2024. His death has left a - John McCullough, Carencro, LA Community Mourns Beloved Family Member OmPaix
Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with depression in a study. The drug, called navacaprant, was no better than a placebo in the trial, the first of three Phase 3 studies the company is running in hopes of gaining U.
The markups helped the pharmacy-benefit managers reap $7.3 billion from 2017 to 2022, the FTC found.
(833) 317-6278 
